The signalling pathways initiated by members of the transforming growth factor-β (TGFβ) 17 family of cytokines control many metazoan cellular processes, including proliferation and 18 differentiation, epithelial-mesenchymal transition (EMT), and apoptosis. TGFβ signalling is 19 therefore strictly regulated to ensure appropriate context-dependent physiological 20 responses. In an attempt to identify novel regulatory components of the TGFβ signalling 21 pathway, we performed a pharmacological screen using a cell line engineered to report the 22 endogenous transcription of the TGFβ-responsive target gene PAI-1. The screen revealed 23 that small-molecular inhibitors of salt-inducible kinases (SIKs) attenuate TGFβ-mediated 24 transcription of PAI-1 without affecting receptor-mediated SMAD phosphorylation, SMAD 25 complex formation or nuclear translocation. We provide evidence that genetic inactivation 26 of SIK isoforms also attenuates TGFβ-dependent transcriptional responses. Pharmacological 27 inhibition of SIKs using multiple small-molecule inhibitors potentiated apoptotic cell death 28 induced by TGFβ stimulation. Our data therefore provides evidence for a novel function of 29 SIKs in modulating TGFβ-mediated transcriptional and cellular responses. 30 31 Previously, we developed an endogenous transcriptional reporter cell line for the TGFβ 62 pathway using CRISPR-Cas9 genome editing technology 21 by inserting firefly (Photinus 63 pyralis) luciferase and green fluorescent protein (GFP) at the native TGFβ-responsive target 64 gene plasminogen activator inhibitor 1 (PAI-1) locus ( Figure 1A) . The transcription of PAI-1 is 65 induced in response to TGFβ signals in different cell types in a SMAD-dependent 66 manner 22,23 . Moreover, the promoter region of the endogenous PAI-1 gene has been 67 frequently utilised in order to generate conventional luciferase-based overexpression 68 reporter systems for the study of TGFβ-mediated transcriptional regulation 24 . In order to 69 identify novel regulatory components of the TGFβ pathway, we performed a 70 pharmacological screen in this endogenous TGFβ-responsive transcriptional reporter cell 71 line using a panel of small-molecules obtained from the MRC International Centre for Kinase 72 Profiling at the University of Dundee. The panel consisted predominantly of selective and 73 potent inhibitors of protein kinases but also included a small number of compounds which 74 target components of the ubiquitin-proteasome system (UPS). The screen identified salt-75 inducible kinases (SIKs), which are members of the AMPK-activated protein kinase (AMPK)-76 related subfamily of serine-threonine specific kinases 25,26 , as potential novel regulators of 77 TGFβ-mediated gene transcription. In this study, we have therefore investigated the role of 78 SIKs in regulating the TGFβ signalling pathway. 79 80 Results 81
Introduction 33
Signalling pathways initiated by the TGFβ family of cytokines are amongst the most 34 prevalent and diverse in metazoan biology and regulate a multitude of processes including 35 cellular proliferation and differentiation, epithelial-mesenchymal transition (EMT), cell 36 migration, immunoregulation and apoptotic cell death in a context-dependent manner 1-6 . 37 Consequently, perturbations within the signalling pathway have been associated with the 38 pathogenesis of many human disorders including cancer. For example, in normal epithelial 39 cells, TGFβ has a tumour suppressive function, principally through its ability to induce 40 cytostasis and apoptotic cell death [7] [8] [9] . In contrast, during tumour progression, the 41 suppressive effect of TGFβ is lost and, in certain cancers, corruption of the signalling 42 pathway can result in TGFβ exerting a pro-oncogenic effect 7,10,11 . Inhibition of the TGFβ 43 pathway has therefore been proposed as a potential therapeutic strategy in certain 44 pathological contexts 12, 13 . However, the highly pleiotropic and context-dependent nature of 45 TGFβ signalling has provided a considerable challenge for pharmacological intervention 14 . 46
Elucidating the context-dependent regulatory mechanisms underlying TGFβ signalling is 47 therefore of considerable importance in identifying novel therapeutic interventions. 48 49 TGFβ signalling is initiated upon the binding of TGFβ ligand dimers to cognate 50 transmembrane receptor serine-threonine protein kinases to form activated 51 heterotetrameric receptor complexes containing two type I receptors and two type II 52 receptors 15 . This allows the constitutively active type II receptor to phosphorylate multiple 53 serine and threonine residues within the cytoplasmic domain of the type I receptor, which 54 enables the type I receptor to bind and phosphorylate the SMAD transcription factors 2/3 55 (SMADs2/3) at the Ser-Xxx-Ser motif at the carboxy-terminal tail [16] [17] [18] . Receptor-mediated 56 phosphorylation of R-SMADs facilitates interaction with the co-SMAD, SMAD4, followed by 57 accumulation in the nucleus, where the SMAD complex co-operates with different 58 transcriptional co-regulators to modulate the expression of hundreds of target genes in a 59 cell type-and context-dependent manner [18] [19] [20] . 60 61 4 format pharmacological screen was performed to identify potential novel regulators of the 93 TGFβ pathway ( Figure 1E ). TGFβR1 inhibitors SB-505124 27,28 and A 83-01 29 served as positive 94 controls, while DMSO a negative control. All compounds were used at 1 µM final 95 concentration. Both SB-505124 and A 83-01 significantly inhibited TGFβ-induced luciferase 96 activity compared with DMSO controls (Figure 1F and 1G) . Additionally, D4476 and 97 LDN193189, also significantly inhibited TGFβ-induced luciferase activity. D4476 was initially 98 identified as an inhibitor of TGFβR1 30 , although subsequent in vitro profiling revealed that is 99 inhibited casein kinase 1 (CK1) with greater potency 31 . LDN193189 is an ATP-competitive 100 inhibitor of the BMP type I receptor kinases 32 . However, at 1 µM concentration it also 101 inhibits the TGFβR1 28 . The majority of the compounds used in the screen did not 102 significantly affect TGFβ-induced luciferase reporter activity. Interestingly however, we 103 observed that HG-9-91-01, a potent ATP-competitive inhibitor of salt-inducible kinase (SIK) 104 isoforms 33 , significantly attenuated TGFβ-induced luciferase activity ( Figure 1F and 1G) , 105 suggesting a possible role for SIKs in TGFβ-induced transcription. 106 107
Characterisation of SIK inhibitors in the context of TGFβ signalling 108
To explore the role of SIKs in TGFβ signalling further, in addition to HG-9-91-01, we utilised 109 MRT199665, a structurally distinct inhibitor of SIK isoforms 33 (Figure 2A ). MRT199665 also 110 suppressed TGFβ-induced luciferase activity in U2OS-2G cells, as potently as SB-505124 and 111 HG-9-91-01 ( Figure 2B ). Both HG-9-91-01 and MRT199665 inhibited the phosphorylation of 112 a known SIK substrate CRTC3 at S370 33-35 compared with DMSO control ( Figure 2C ). Because 113 kinase inhibitors often display off-target inhibition, we tested whether the attenuation of 114
TGFβ-induced luciferase activity by HG-9-91-01 and MRT199665 occurred as a result of the 115 off-target inhibition of the TGFβR1 upstream of SMAD2/SMAD3 phosphorylation. HG-9-91-116 01 substantially inhibited TGFβ-induced SMAD3 phosphorylation, to a similar extent as SB-117 505124, compared to DMSO controls, whereas MRT199665 did not ( Figure 2D ), suggesting 118 that HG-9-91-01 could inhibit either type I or type II TGFβ receptors. Indeed, at 119 concentrations of 0.1, 1 and 10 µM in vitro, HG-9-91-01 inhibited TGFβR1 (ALK5) kinase 120 activity, whereas MRT199664 did not ( Figure 2E ). Because of this off-target inhibition of 121 TGFβR1 by HG-9-91-01, we decided to employ MRT199665 as SIK inhibitor for subsequent 122 experiments. 123 expression 140
We employed genetic approaches to test the impact of SIK kinase activity on TGFβ 141 signalling. SIKs are members of the AMP-activated protein kinase (AMPK)-related subfamily 142 of serine-threonine protein kinases that require LKB1-mediated phosphorylation of a 143 conserved threonine residue within the activation loop in order to become catalytically 144 active 25,26 ( Figure 4A ). In LKB1-deficient WT HeLa cells 36-38 , TGFβ 1 induced a 1.5-fold 145 increase in PAI-1 mRNA expression relative to unstimulated controls. However, stable 146 overexpression of catalytically active LKB1 (LKB1 WT ), but not catalytically inactive mutant 147 (LKB1 D194A ), in WT HeLa cells significantly enhanced the TGFβ-induced transcription of PAI-1 148 mRNA ( Figure 4B ) as well as PAI-1 protein levels ( Figure 4C ), although the levels of LKB1 WT 149 restored in HeLa cells was substantially higher than the LKB1 D194A mutant ( Figure 4C ). 150
151
The catalytic activity of SIK isoforms can be ablated via mutation of the activation loop 152 threonine to alanine 39 , which abolishes LKB1-mediated phosphorylation. Indeed, in mouse 153 embryonic fibroblasts (MEFs) derived from embryos harbouring homozygous SIK2 T175A and 154 6 SIK3 T163A genotypes 39 , the phosphorylation of CRTC3 at S370 is substantially reduced 155 compared to WT control MEFs ( Figure 4D) . A time-course treatment WT MEFs with TGFβ 1 156 resulted in robust SMAD3 phosphorylation and increase in PAI-1 protein levels at 6 hours 157 ( Figure 4E ). When homozygous SIK2 T175A /SIK3 T163A MEFs were subjected to TGFβ stimulation 158 for 6 hours, the induction of PAI-1 protein expression was substantially attenuated 159 compared with WT MEFs, despite the observation of higher SMAD3 phosphorylation in the 160 SIK2 T175A /SIK3 T163A mutant MEFs ( Figure 4F ). Consistent with this, the relative PAI-1 mRNA 161 expression in response to TGFβ stimulation was significantly reduced in MEFs derived from 162 two independent homozygous SIK2 T175A /SIK3 T163A mice relative to WT MEFs ( Figure 4G ). 163
164

Impact of SIK isoforms on TGFβ-dependent proliferative responses 165
TGFβ inhibits epithelial cell proliferation, in part through transcriptional upregulation of 166 cyclin-dependent kinase (CDK) inhibitors p21 CIP1 and p27 KIP1 and downregulation of the 167 proto-oncogene c-Myc 1,4,7 . In HaCaT cells, we observed an increase in endogenous p27 KIP1 168 and p21 CIP1 protein levels and a decrease in c-Myc protein levels over a 24-hour time course 169 of TGFβ treatment ( Figure 5A ). Rather surprisingly, treatment of HaCaT cells with 170 MRT199665 resulted in increased expression of both p21 CIP1 and p27 KIP1 even in the absence 171 of TGFβ treatment, and this increase was more pronounced after stimulation of cells with 172 TGFβ compared to DMSO controls ( Figure 5B ). This suggested that inhibition of SIKs alone 173 may exert cytostatic effects. When we analysed the proliferation of HaCaT cells over a 174 period of 160 hours, the control cells displayed a typical sigmoid growth curve, while TGFβ 175 treatment caused a significant inhibition of proliferation after 100 hours ( Figure 5C ). Under 176 these conditions, MRT199665 profoundly suppressed cell proliferation at all time points, 177 regardless of TGFβ treatment ( Figure 5C ). We also observed a substantial increase in p27 KIP1 178 levels in MEFs derived from homozygous SIK2 T175A /SIK3 T163A KI mice relative to WT mice 179 irrespective of TGFβ stimulation ( Figure 5D ), suggesting that SIK kinase activity plays a 180 fundamental role in suppressing p27 KIP1 protein levels. To further confirm that SIK inhibition 181 promotes cytostasis independent of TGFβ stimulation, we exploited SMAD3 -/-HaCaT cells 182 and showed that treatment of both WT and SMAD3 -/-HaCaT cells with MRT199665 resulted 183 in an increase in p21 CIP1 and p27 KIP1 levels compared with untreated control cells ( Figure 5E Figure 6A ). The 206 expression of pro-apoptotic factor Bim was observed at 48-72 hours ( Figure 6A ). In these 207 cells, SIK inhibitors HG-9-91-01 and MRT199665 resulted in reduction of phospho-CRTC3-208 S370 ( Figure 6B ). The TGFβ-induced cleavage of caspase-3 and PARP at 24 hours was 209 blocked by SB-505124 ( Figure 6C ). Interestingly, in cells incubated with MRT199665 and 210 TGFβ 1 , the appearance of cleaved caspase-3 and PARP were substantially enhanced 211 compared with TGFβ-treated DMSO controls ( Figure 6C ). In the absence of TGFβ 1 , 212 MRT199665 alone did not induce the cleavage of caspase-3 and PARP ( Figure 6D ). 213 Furthermore, MRT199665+TGFβ 1 treatment resulted in the maximal and more pronounced 214 appearance of cleaved caspase-3 and PARP much earlier (12 hours) than TGFβ 1 alone 215 treatment ( Figure 6D ). When we monitored apoptosis using Annexin V and DAPI staining, NMuMG cells with bosutinib for 24 hours substantially enhanced the TGFβ-induced levels of 239 cleaved caspase-3 and PARP to a similar extent as MRT199665 ( Figure 7G ), suggesting that 240 the increased TGFβ-induced apoptosis caused by bosutinib is likely due to its ability to 241 inhibit SIK isoforms. 242 243
SIKs do not appear to affect SMAD2/3 phosphorylation and their nuclear translocation 244 directly 245
We sought to investigate the molecular mechanisms by which SIK2/SIK3 might regulate 246 TGFβ signalling. To explore whether SIKs exert effects on TGFβ signalling through direct 247 phosphorylation of SMAD proteins, in vitro kinase assays were performed. GST-SIK2 and 248 GST-SIK3, but not MBP-SIK1, phosphorylated SMAD2, SMAD3 and SMAD4 in vitro ( Figure  249 9 S1), while SIK inhibitor HG-9-91-01 blocked SMAD3 phosphorylation ( Figure S2 ). Mass 250 spectrometry identified Thr247 as the predominant SIK2/3 phosphorylated residue on 251 SMAD3. This residue is conserved in SMAD2, SMAD3, SMAD4 and SMAD9 proteins ( Figure  252 8A). The TGFβ-induced transcription of PAI-1 has been previously reported to be specific to 253 SMAD3 23,49 . Consistent with this, treatment of wild type and SMAD3 -/-HaCaT cells with 254 human TGFβ 1 resulted in C-terminal phosphorylation of SMAD2 however PAI-1 expression 255 was completely abrogated in SMAD3 -/cells but not in WT cells ( Figure 8B ). Transient 256 restoration of SMAD3 expression with FLAG-SMAD3 WT was sufficient to partially restore 257 TGFβ-induced PAI-1 expression ( Figure 8D ). However, restoration of the SIK-phospho-258 deficient mutant FLAG-SMAD3 T247A in SMAD3 -/cells also restored TGFβ-induced PAI-1 259 expression, to similar levels observed with SMAD3 WT (Figure 8B ), suggesting that 260 phosphorylation of SMAD3 at Thr247 by SIKs is unlikely to explain effects of SIKs in TGFβ 261 signalling. 262 263 Next, we whether SIK2/SIK3 inhibition disrupts the formation of SMAD2/SMAD3-SMAD4 264 complexes or nuclear accumulation of SMADs. In U2OS cells stably overexpressing GFP-265 SMAD4, neither the basal nor TGFβ-induced increase in co-precipitation of SMAD2/3 in GFP-266 SMAD4 IPs was affected by treatment of cells with MRT199665 ( Figure 8C TGFβ responses, thereby limiting potential consequences of inhibiting the TGFβ pathway in 345 its entirety. Of course, as discussed above, SIKs themselves are known to control other 346 pathways, including immune signalling, and these need to be considered carefully. Taking 347 into consideration that the clinically approved TKIs dasatinib and bosutinib, which also 348 potently inhibit SIK isoforms 45, 46 , are administered to patients safely, it is conceivable that 349 more specific SIK inhibitors could be applied to target certain TGFβ-associated pathologies. NMuMG cells were incubated with the required cytokine/inhibitor combinations. Following 496 this, both adherent and non-adherent (i.e. apoptotic) cells were collected into 50 mL conical 497 centrifuge tubes, pelleted by centrifugation (300 x g, 2 minutes) and washed once using cold 498 1x DPBS. Cells were subsequently centrifuged (300 x g, 2 minutes), the cell pellets were 499 resuspended in Annexin Binding Buffer, ABB (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl 2 , 500 pH 7.4) and transferred to 1.5 mL microcentrifuge tubes. The required cell suspension 501 samples were then incubated with Annexin V, Alexa Fluor 488 conjugate (Invitrogen; 502 A13201) for 15 minutes at RT and protected from light. The appropriate samples were 503 subsequently incubated with 5 µg mL -1 DAPI (4',6-diamidino-2-phenylindole) (Invitrogen). 
